(Q43837146)

27 November 2017

title

Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma (English)

1 reference

27 November 2017

Ken-Ryu Han

1

1 reference

27 November 2017

Allan J Pantuck

2

1 reference

27 November 2017

Matthew H T Bui

3

1 reference

27 November 2017

Oleg Shvarts

4

1 reference

27 November 2017

Danielo G Freitas

5

1 reference

27 November 2017

Amnon Zisman

6

1 reference

27 November 2017

Bradley C Leibovich

7

1 reference

27 November 2017

Frederick J Dorey

8

1 reference

27 November 2017

Barbara J Gitlitz

9

1 reference

27 November 2017

Robert A Figlin

10

1 reference

27 November 2017

Arie S Belldegrun

11

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

27 November 2017

1 reference

27 November 2017

volume

61

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

314-319

1 reference

27 November 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

1 reference

7 January 2021

Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Prognostic relevance of intracaval neoplastic extension for patients with renal cell cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Renal cell carcinoma extending to the renal vein and inferior vena cava: results of surgical treatment and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2902163-5

7 January 2021

10.1016/S0090-4295(02)02163-5

Identifiers

DOI

1 reference

27 November 2017

1 reference